The Strasbourg site is located in the Illkirsh-Graffenstaden Innovation Park.

Covering an area of 4900 sq meters, the site has been the first viral vectors facility in Europe (1994).

The facility has been specialized in viral vectors development and manufacturing for 25+ years. Equipped with four independent suites focusing on development and scalable production, our capabilities are fully flexible to support your innovation and make your project a success. A dedicated fill & finish suite for the manufacturing of your drug product can manage up to 10,000 vials/batch.

Our integrated Quality Control laboratory is operational design and execute a detailed and robust process and analytical development plan, phase appropriate, accordingly to your product specification and overall project milestones.

Our team of experts bring extensive experience in viral vectors field.



options to

Suite 1 : Grade A/C
Suspended & adherent (microcarriers) cells

up to
60 sqm

Roller bottle
up to
17 sqm

Suite 2 : Grade A/B
Adherent cells

Up to
10,000 vials
per batch

Suite 3 : F&F. Isolator Grade A/C

Process development & process transfer

QC laboratories: ~400 sqm and 38 analytical experts

4 Rue Laurent Fries
67400 Illkirch-Graffenstaden FRANCE
Phone: +33 3 88 55 10 00



Inspection history

ABL is inspected routinely by the French National Agency for the Safety of Medicines and Health (ANSM), approved and GMP licensed in accordance with EMA (available from EudraLex). Depending on the progress of your projects, our Strasbourg site can assist you in the production of commercial batches.

Last ANSM (French National Agency for the Safety of Medicines and Health) inspections:
No critical observation reported

March 2021
Routine inspection
October 2018
Routine inspection
May 2016
1st ABL Europe inspection
Powered by